Expanded access to olanzapine/samidorphan for teens with schizophrenia or bipolar disorder
Part of Mental health clinical trials.
This program provides continued access to the study medication OLZ/SAM (a combination of two medicines) for children and teenagers who have schizophrenia or bipolar disorder and who have already completed the main study. The goal is to let them keep receiving the treatment under medical supervision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the 52-week ALKS 3831-A313 study.
- You must not be a danger to yourself or others, and you need family support.
- Your doctor must believe you will benefit from continued treatment with OLZ/SAM.
- You must be able to be treated as an outpatient.
- You must agree to use contraception as required by the study.
- Your parent or legal guardian must be reliable and agree to support you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how safe a kid’s ongoing treatment is over a longer period. It is mainly for children who already finished a related study and may benefit from continuing the same medicines.
This Phase 3 study tests a treatment aimed at reducing unhealthy weight gain in teens with schizophrenia or bipolar I disorder, using changes in BMI (a height-and-weight measure). It may help families who are concerned about weight changes that can happen with some psychiatric medicines.
This trial tests a new combination tablet (olanzapine-samidorphan) for adults with schizophrenia. It aims to see if it helps control symptoms while potentially reducing weight gain, which can be a side effect of some schizophrenia medicines.
This study tests whether a combination of a daily medication (olanzapine-samidorphan) and a structured exercise program can help people with schizophrenia, schizoaffective disorder, or bipolar disorder improve their health and well-being.
This study looks at how well patients with bipolar disorder do while taking the medication olanzapine. You will continue your regular treatment, and answer questions about your experience.
This Phase 1 trial tests whether BXCL501 is safe and can help reduce agitation in children and teens who have bipolar disorder or schizophrenia. You may be considered if your agitation is significant during screening, but certain recent medication and health factors can make you ineligible.
Hear when a new Bipolar 1 Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.